Articles Tagged With:
-
CAUTIs: What to Do, What Not to Do
New compendium recommendations by the nation’s leading infection control groups on catheter-associated urinary tract infections (CAUTIs) emphasize that, in most cases, screening for asymptomatic bacteriuria does more harm than good.
-
What Is in Your Laundry? The Threat of Mucormycosis
Even pressed and folded, so-called “hygienically clean” hospital laundry can harbor fungal pathogens, sometimes in sufficient number to cause fatal mucormycosis infections in high-risk patients, outbreak investigators reported at the 2023 conference of the Association for Professionals in Infection Control and Epidemiology.
-
Misinformation: The Many-Headed Hydra
Social media platforms have become the Wild West of misinformation, and current indications suggest this is going to continue and possibly expand, said Donna Nucci, RN, MS, CIC, director of infection prevention, Yale New Haven Health.
-
Statins Might Lower Risk of Recurrent Stroke
Patients in Denmark who suffered an intracerebral hemorrhage and were taking cholesterol-lowering medication were less likely to experience another stroke.
-
Preventing and Reversing Cardiovascular Disease Through Lifestyle Modification
Cardiovascular disease (CVD) is the leading cause of death globally and in the United States. Identifying and targeting cardiovascular risk factors is essential for the prevention and long-term management of CVD. Traditionally, factors for the onset and progression of CVD were thought to be mostly genetic. It is now well established that several of these factors are lifestyle mediated. Behavioral changes significantly influence the interplay between a healthy lifestyle and the genetic risk of heart disease. To further understand the challenges with preventing and reversing CVD, providers need to consider the alarming prevalence of risk factors among the U.S. population.
-
Is Planned Complete Revascularization After Myocardial Infarction Wise for Older Patients?
Among patients at least age 75 years presenting with acute myocardial infarction and multivessel coronary disease, physiology-guided complete revascularization led to a lower risk of major adverse cardiovascular events at one year vs. culprit lesion-only percutaneous coronary intervention.
-
High-Impact Clinical Trials from the European Society of Cardiology Congress 2023
The following is an overview of important cardiology research presented Aug. 25 through Aug. 28 in Amsterdam and online during the ESC Congress 2023.
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
-
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
Adding a GLP-1 RA in a subgroup of type 2 diabetes patients on baseline SGLT2 inhibitor therapy revealed GLP-1 RA reduces major adverse cardiovascular event rates, regardless of baseline SGLT2 use.
-
An RNA Shot for Hypertension?
One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.